Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis - Related Studies

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

This study has been completed.

Study NCT00035334. Last updated on February 13, 2006. Information provided by Bellus Health Inc

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Secondary (AA) Amyloidosis
		Rheumatoid Arthritis
		Nephrotic Syndrome
		Familial Mediterranean Syndrome
		Kidney Diseases
		Gastrointestinal Diseases

2	Additional conditions recognized in this trial
		Amyloidosis
		Arthritis
		Arthritis, Rheumatoid
		Neoplasm Metastasis
		Syndrome

3	More general conditions related to this trial
		Autoimmune Diseases
		Connective Tissue Diseases
		Digestive System Diseases
		Disease
		Immune System Diseases
		Joint Diseases
		Metabolic Diseases
		Musculoskeletal Diseases
		Neoplasms
		Neoplastic Processes
		Nephrosis
		Pathologic Processes
		Rheumatic Diseases
		Urologic Diseases

4	Sponsors listed in this trial
		Bellus Health Inc
		FDA Office of Orphan Products Development